Hospitalisation among vaccine breakthrough COVID-19 infections

https://www.thelancet.com/journals/la...

Robust vaccine efficacies at preventing severe symptomatic disease

Breakthrough SARS-CoV-2 infections in fully vaccinated

https://covid.joinzoe.com/post/worryi...

Impact of vaccination on admission to hospital

Patients with confirmed SARS-CoV-2 infection

Yale New Haven Health System, Connecticut

Between March 23 and July 1, 2021

Patients were considered fully vaccinated 14 days after second dose

969 patients were admitted PCR positive

172 (18%) of 969 patients had received at least one vaccine dose

103 had received a partial vaccine course

15 had received a complete course

54 were fully vaccinated

Among the 54

25 (46%) patients were asymptomatic

4 (7%) had mild disease

11 (20%) had moderate disease

14 (26%) had severe or critical illness

4 (7%) required ICU

1 required ventilation

3 died

Among those with severe or critical illness

Median age 80·5 years

Pre-existing comorbidities in the 14 patients with severe or critical illness

Body–mass index more than 25 kg/m² (n=9)

Cardiovascular disease (n=12)

Lung disease (n=7)

Malignancy (n=4)

Type 2 diabetes (n=7)

Immunosuppressive agent (n=4)

Difference between vaccines

13 of 14 patients had received BNT162b2, Pfizer

1 of the 14 had received mRNA-1273, Moderna

0 of the 14 had received Ad.26. COV2.S, J and J

May 17, 2021, vaccine doses in Connecticut

Pfizer, 1, 358, 175

Moderna, 1, 044, 420

J and J, 267, 000